IFF outlines a Scent recovery led by a strengthened R&D engine, including a pipeline of distinctive molecules and delivery systems, and a go-to-market revival for Consumer Fragrance. Fine Fragrance benefits from improved execution amid Middle East volatility, with an expected Q3 softness and Q4 rebound, while R&D investment positions the company for stronger competitive positioning through 2027.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Management frames the recovery as execution behind a strengthened R&D engine: the company says that 2.5 years ago the R&D pipeline “was not what it should have been,” while today it has a “very strong R&D capability,” “leading-edge new Fine Fragrances and Consumer Fragrances,” and a “great pipeline of molecules as well as delivery systems.” 1
The strategic intent also includes investing in R&D and growing market share back as part of getting the “balance” right in Scent. 2
Fine Fragrance performance is described as affected by uncertainty and volatility in the Middle East, but management reports that the team managed the challenges such that Fine Fragrance finished “up slightly positive” versus an expected down “mid-single digits” entering the quarter. 3
For the recovery path through the year, management expects softer Q3 (after a very strong prior-year comp) and recovery in Q4, with the Middle East crisis continuing as a key moving piece. 3
Management attributes Consumer Fragrance progress to rebuilding R&D capability and the go-to-market approach with customers and driving market share gains. 4
They also specifically cite “compounds” execution as a major operational underpinning for the Consumer Fragrance rebound. 4
In Scent, Fragrance Ingredients is highlighted as a major driver of Scent’s quarter performance: the company reports Q2 sales were up 8% and cites Fragrance Ingredients growing “north of 20%,” including both the year-over-year comparison (against a down ~10% or more prior-year period) and strategic leverage of the synthetics portfolio due to macroeconomic/supply-chain factors and higher Brent crude prices. 3
Management expects that as conditions settle, growth will “normalize” in the second half with a shift back toward higher-value-added ingredients versus traditional synthetics, and that this normalization is slightly under pressure year-over-year going forward. 4
For Fine Fragrance, management provides both quarter-shape and full H2 framing:
They also characterize Fine Fragrance growth in the quarter as low-single-digit, inclusive of the impact of the Middle East conflict. 5
For Consumer Fragrance, management’s guidance emphasizes normalization:
Management says progress over the last 2.5 years has built:
This is framed as necessary to rebuild capability and support continued commercial execution through 2027. 21
While part of the 2026/2027 story is driven by operational conditions and normalization in Fragrance Ingredients, management connects that ingredient strategy to longer-term competitiveness:
This directly implies R&D/innovation and product development are being positioned to compound into 2027 outcomes, particularly in ingredient differentiation and product performance. 4
Management’s R&D plan is not described as laboratory-only; it explicitly includes rebuilding:
The call also frames innovation reinvestment as a pillar of the Remainco strategy and emphasizes continuing to reinvest to sustain the “circle” of innovation → better growth → margin expansion → continued reinvestment: R&D as a percentage of sales is “8% to 9%,” and they stress the need to critically continue to reinvest because innovation matters. 6
They also mention overall transformation progress supported by reinvestment and step changes. 7
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
IFF outlines a Scent recovery anchored in disciplined reinvestment in R&D, a strengthened pipeline, and careful navigation of Middle East volatility, with 2H 2026 expected growth in Fine Fragrance and a normalization to low single digits in Consumer Fragrance. The multi-year R&D plan targets 2027 by advancing molecules, delivery systems, and leading‑edge perfumers to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF frames Scent's recovery around a rebuilt, stronger R&D pipeline and innovative delivery systems, with Fragrance Ingredients accelerating on higher-value inputs. For H2, Fine Fragrance should see a softer Q3 followed by a stronger Q4, while Consumer Fragrance is expected to grow in the low single digits as R&D and go-to-market efforts support market-share gains—backed by an ongoing 8-9% R&D investment to fuel 2027 growth.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery hinges on a rebuilt R&D engine, stronger go-to-market execution, and resilient Fine Fragrance performance amid regional volatility. In H2, Fine Fragrance is expected to deliver mid-single-digit growth with a soft Q3 and stronger Q4, while Consumer Fragrance normalizes to low single-digit gains; the company reiterates a 2027-focused plan to sustain innovation through heightened R&D investment and a robust molecule and delivery-systems pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Q2 2026 discussion frames a Scent recovery driven by a rebuilt R&D pipeline and stronger Consumer Fragrance execution, with Fine Fragrance set for Q4 recovery. The company emphasizes a longer-term R&D and ingredients strategy to support 2027 and beyond.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF’s Scent recovery is anchored in a rebuilt R&D engine, a stronger fragrance ingredients business, and a strategically paced turnaround for Fine and Consumer Fragrances in the second half of 2026. The discussion also highlights ongoing investments in a broader, more innovative product pipeline and a 2027 plan that relies on go-to-market rebuilds and sustained R&D spend to sustain growth and margin expansion.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines that Scent’s rebound rests on a rebuilt R&D engine, a stronger pipeline, and improved go-to-market execution, with Fine Fragrance soft in Q3 and stronger in Q4, and Consumer Fragrance normalizing to low single-digit growth. The plan ties 2027 readiness to sustained R&D investment and closer customer collaboration, while Fragrance Ingredients normalization poses a near-term headwind before a shift to higher-value natural products strengthens longer-term competitiveness.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is driven by a rebuilt R&D engine and a stronger end-to-end pipeline, including molecules and delivery systems, alongside leading-edge new fragrances. In H2, Fine Fragrance should see softer Q3 and stronger Q4 amid volatility, while Consumer Fragrance normalizes to low single-digit growth as market share gains persist and go-to-market reforms take hold. The 2027 plan centers on sustaining an 8-9% of sales R&D investment and leveraging innovation to fortify competitive positioning.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF maps a resilient Scent recovery driven by Fine Fragrance stabilization, Consumer Fragrance R&D and go-to-market gains, and Fragrance Ingredients momentum, with normalization expected as Scent shifts away from synthetics. For 2H, Fine Fragrance is softer in Q3 and stronger in Q4 (mid-single-digit growth), while Consumer Fragrance should trend to low single digits. The R&D rebuild aims to fortify competitive positioning into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF Scent's recovery hinges on three pillars: Fine Fragrance execution amid Middle East volatility, a Consumer Fragrance strategy built around rebuilding R&D capability and a go-to-market approach to regain market share, and a Fragrance Ingredients tailwind in Q2 that is normalizing as the portfolio shifts toward higher-value ingredients. In H2 2026, Fine Fragrance is expected to maintain mid-single-digit growth while Consumer Fragrance stabilizes at low single-digit, with R&D reinvestment driving a stronger 2027 pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a science-led recovery for Scent, driven by fragrance ingredients momentum, Fine Fragrance resilience, and a rebuilt Consumer Fragrance GTM with a stronger R&D pipeline. The company expects Q3 softness followed by a stronger Q4 in H2 2026, underpinned by an R&D-led plan for 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a path for Scent recovery anchored in a rebuilt R&D engine and an integrated go-to-market strategy, with Fine Fragrance facing a softer Q3 before a Q4 rebound and Consumer Fragrance expected to normalize to low single-digit growth in 2H 2026. The plan emphasizes higher-value ingredients and sustained R&D investment into 2027 to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by a rebuilt R&D engine, with a stronger pipeline and selective management of Middle East volatility. In 2H, Fine Fragrance is expected to hover in mid-single digits (softer in Q3, stronger in Q4) while Consumer Fragrance should normalize to low single digits as go-to-market and R&D revitalization drive market share. The 2027 plan centers on sustained R&D investment and higher-value natural ingredients.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi